Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Merck
McKinsey
Johnson and Johnson
Medtronic

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ERAVACYCLINE DIHYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Eravacycline Dihydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01265784 Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections Completed Tetraphase Pharmaceuticals, Inc. Phase 2 2011-01-01 This is a Phase 2, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of two dose regimens of TP-434 compared with ertapenem in the treatment of adult community-acquired complicated intra-abdominal infections (cIAIs).
NCT01844856 Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections Completed Tetraphase Pharmaceuticals, Inc. Phase 3 2013-08-01 This is a Phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety, and pharmacokinetics of eravacycline compared with ertapenem in the treatment of adult complicated intra-abdominal infections (cIAI).
NCT01941446 A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization Completed Tetraphase Pharmaceuticals, Inc. Phase 1 2013-03-01 This is a randomized, placebo- and positive-controlled (moxifloxacin), 3-period, 3-way crossover thorough QT study, which includes a Screening Period, Treatment Periods (1 through 3), and a Follow-up Visit. Subjects will be confined to the investigational site for 4 nights/3 days during Period 1 and for 3 nights/2 days during Periods 2 and 3. There will be a minimum of a 14 day washout between treatments.
NCT01978938 Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections Active, not recruiting Tetraphase Pharmaceuticals, Inc. Phase 3 2013-12-01 This is a Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Levofloxacin in Complicated Urinary Tract Infections (cUTI)
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eravacycline Dihydrochloride

Condition Name

Condition Name for Eravacycline Dihydrochloride
Intervention Trials
Complicated Intra-abdominal Infections 2
Complicated Urinary Tract Infections (cUTI) 1
Complicated Urinary Tract Infections 1
Normal Healthy Subjects 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Eravacycline Dihydrochloride
Intervention Trials
Infection 6
Communicable Diseases 5
Intraabdominal Infections 3
Urinary Tract Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Eravacycline Dihydrochloride

Trials by Country

Trials by Country for Eravacycline Dihydrochloride
Location Trials
United States 32
India 5
Romania 5
Bulgaria 4
Latvia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Eravacycline Dihydrochloride
Location Trials
California 4
Florida 3
Indiana 2
Alabama 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Eravacycline Dihydrochloride

Clinical Trial Phase

Clinical Trial Phase for Eravacycline Dihydrochloride
Clinical Trial Phase Trials
Phase 3 4
Phase 2 1
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Eravacycline Dihydrochloride
Clinical Trial Phase Trials
Completed 6
Recruiting 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Eravacycline Dihydrochloride

Sponsor Name

Sponsor Name for Eravacycline Dihydrochloride
Sponsor Trials
Tetraphase Pharmaceuticals, Inc. 10
Department of Health and Human Services 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Eravacycline Dihydrochloride
Sponsor Trials
Industry 10
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Mallinckrodt
Express Scripts
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.